Caplin Point Laboratories Share Price Falls Over 13% in 3 Sessions; Know Why?

Caplin Point Laboratories has received an update from the US Food and Drug Administration (US FDA) regarding the inspection of its subsidiary Caplin Steriles' manufacturing facility at Gummidipoondi.
The regulator has classified the facility as Official Action Indicated (OAI). The inspection covered the site's injectable and ophthalmic manufacturing operations and took place between August 13 and August 21, 2026.
What Happened During the Inspection?
The US FDA inspection ended with 10 observations, which Caplin Point described as procedural in nature. The company received the regulator's communication on November 16, confirming the OAI classification.
This is an important regulatory development for the subsidiary's facility. However, the company has said it does not expect the classification to have a material impact on its financials or operations.
Will Manufacturing Continue?
According to the exchange filing, the Gummidipoondi facility continues to manufacture and supply products.
Caplin Point said it will work with the US FDA to address the observations and show that its corrective and preventive actions are effective and sustainable. It also reiterated its commitment to quality standards and current Good Manufacturing Practices (cGMP).
Read More: Embassy Developments Share Price in Focus; Unveils Embassy ONE Residences!
Caplin Point Laboratories Share Price Performance
As of 18 November 2026, at 1:48 PM, Caplin Point Laboratories share price is trading at ₹2,088.00 per share, reflecting a decline of 7.08% from the previous trading session.
Conclusion
The OAI classification follows the 10 observations recorded during the August inspection. Caplin Point has said there is no material impact on its business at present, and manufacturing at the subsidiary's facility continues. The company will now work with the regulator to address the observations.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Nov 18, 2026, 2:47 PM IST

Team Angel One
- Indoco Remedies Share Price Rises Over 7% in Intraday Trading on November 18, 2026
- Tata Steel Share Price in Focus; Partners with Utility Global for Hydrogen Project
- Karnataka Bank Share Price in Focus; Appoints Udaya Kumar Hebbar as MD and CEO
- SpiceJet Share Price Hits 5% Upper Circuit Ahead of Board Fundraising Meeting
- Ashoka Buildcon Share Price Surges Over 3%; Emerges as L-1 Bidder for NHAI Project in Gujarat




